a physician a building location a clinical trial a department
menu
BCM - Baylor College of Medicine

Giving life to possible

Parkinson's Disease Center and Movement Disorders Clinic

Botulinum Toxin for Dystonia and Other Disorders

Botulinum toxin (BTX) has been used at Baylor College of Medicine Movement Disorders Clinic in the treatment of dystonia and related disorders since 1983. Its safety and efficacy has been established, partly as a result of the pioneering work at the Movement Disorder Clinic. The first double-blind, placebo controlled trial of BTX in cranial-cervical dystonia was conducted at Baylor and the findings were used to obtain the initial approval for BTX by the Food and Drug Administration.

Dystonia is a neurological condition manifested by involuntary contractions (spasms) of muscles producing twisting, squeezing or pulling movements and abnormal postures. Examples of dystonia include blepharospasm (spasms of eyelids causing involuntary eye closure), cervical dystonia or torticollis (spasms of neck muscles causing twisting and other movements of the neck, abnormal head posture, and neck pain), laryngeal dystonia or spasmodic dysphonia (spasms of vocal cords causing a strained or breathy voice), oro-mandibular (mouth and jaw spasms) dystonia, and task-specific dystonias (writer's cramps). In addition to dystonias, BTX has been used also to relieve other focal spasms, such as hemifacial spasms, tremors, tics, spasticity, and other movement disorders. At Baylor Movement Disorders Clinic, BTX has been also used to treat muscle contraction (tension) and migraine headaches, excessive drooling (sialorrhea), excessive sweating (hyperhidrosis), and other conditions for which BTX has been found to be effective. Studies involving thousands of patients have demonstrated the usefulness and safety of BTX treatments in these conditions.

BTX is a protein that acts by binding to certain nerve endings thus preventing the release of the neurotransmitter acetylcholine. An injection of BTX into the muscle blocks transmission of impulses from the nerve to the muscle causing local and temporary weakness of the target muscle. This process, called "chemodenervation," provides effective relief of dystonias and other disorders manifested by abnormal and unwanted muscular contractions or abnormal secretions. The onset of improvement is often noted within a few days after injection and the benefits usually wear off after 3 to 6 months at which time a repeat injection is needed. Because BTX acts only locally without spreading into the circulation, it does not usually cause any systemic reactions. Most patients obtain safe and substantial relief, but a few experience side effects after the treatment. Except for occasional temporary feeling of generalized malaise and weakness, nearly all other side effects are confined to the injected body part. Injections into the eyelids, for example, may result in transient local swelling, droopy eyelids, blurring of vision, and tearing. Injections into the neck muscles may cause temporary neck weakness or pain and difficulties with swallowing. Swallowing problems as well as chewing, speech and voice difficulties may also result from injections into the jaw and vocal cord muscles. Injections into the arm or hand muscles may cause temporary weakness of fingers and hands. These side effects are usually mild, occur infrequently, and most resolve in a few weeks without any specific treatment. If swallowing problems occur, it is advisable to change to a soft or liquid diet. Of course, any troublesome side effects should be reported to the treating or primary care physician.

BTX treatments do not represent a cure, but they usually provide satisfactory relief of symptoms that can be maintained by repeating treatments when the effects of previous BTX injections begin to wear off. Rarely, some patients become unresponsive to the treatment because they develop blocking antibodies. Such immunoresistance is quite uncommon and occurs only after repeated treatments, usually with relatively high doses or when injected more frequently than every 2-3 months. There are several ways that the presence of immunoresistance can be detected. The simplest and least expensive way is to inject small amounts of BTX into the medial portion of right eyebrow. If the eyebrow is weakened by the injection and one week later the patient is unable to contract the muscle on that side while frowning, this indicates that the patient does not have blocking antibodies – no immunoresistance. Besides this unilateral brow injection (UBI) BTX antibodies can be also detected by a mouse bioassay. This test involves sending a frozen blood serum to Northview Pacific Laboratories, 2800 7th St., Berkeley, CA 94710, (510) 548-8440, along with a check for about $200. When the blood sample is forwarded to the Northview Pacific Laboratories by physicians other than those at Baylor, it is important that you are identified as a patient at Baylor College of Medicine and that the results are forwarded to us.

Patients who have become immunoresistant as a result of BTX antibodies no longer respond to subsequent injections with the same type of BTX-A, but may respond to other types of BTX. In December 1989, after extensive laboratory and clinical testing of BTX-A (Botox®, Allergan Pharmaceuticals, California) the Food and Drug Administration approved this biologic as a therapeutic agent in patients with strabismus, blepharospasm and other facial nerve disorders, including hemifacial spasm. In December 2000, the FDA approved Botox® and BTX-B (MYOBLOC®, Solstice Neurosciences, Inc, California) as a treatment for cervical dystonia. In 2002, FDA also approved Botox® for treatment of frown lines between the brows and in 2004 BTX was approved for severe underarm sweating (hyperhidrosis). In 2010, Botox® received approval for spasticity and headaches. Other indications are still pending. Two variants of botulinum toxin A (Dysport® and Xiomen®) were recently introduced to the market in 2009 and 2010 respectively. Both are indicated to treat cervical dystonia in Botox naïve and previously treated patients. Additionally, Xiomen® is indicated to treat blepharospasm in previously treated patients. The procedure requires specialized skills and, therefore, only some centers are performing this treatment. The actual cost of the medication and procedure depends on the total dose and sites required to treat the specific condition and will be determined at the time of the visit and. To cover the cost of the medication and our overhead, we require that all charges for the medication and for the procedure must be paid or a documentation of pre-approval is presented before the treatment visit.

Diagnostic Codes for Filing Insurance Claims

We are genuinely concerned about the cost of the BTX treatments and we are trying to keep the cost as low as possible. Because BTX is approved by the FDA (at least for some indications), many insurance carriers and Medicare provide reimbursement for the cost of the drug and the chemodenervation procedure. The following codes should be used for filing claims:

Diagnostic Codes for Filing Insurance Claims

Diagnosis

Diagnostic Code

Procedure/Treatment (CPT)

Blepharospasm

333.81

64612

Dystonia

333.6

64640

Torticollis

333.83

64613

Hemifacial spasm

351.8

64612

Tremor

781.0

64640

Spasmodic dysphonia

478.75

64640

Botulinum Toxin A (BOTOX©)

-

J0585

Botulinum Toxin B (MYOBLOC™)

-

J3490

Onabotulinumtoxin A (DYSPORT®)

-

J0568

Incobotulinumtoxin B (XEOMIN®)

-

Q2040

©2011 Joseph Jankovic, M.D.

Selected References

Albanese A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011;305:89-90.

Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13(Suppl 3):S362-8.

Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, et al. Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord. 2008 14:443-5.

Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr Treat Options Neurol. 2009;11(1):18-23.

Badarny S, Susel Z, Honigman S. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox. Isr Med Assoc J. 2008;10:520-2.

Benecke R. Xeomin in the treatment of cervical dystonia. Eur J Neurol. 2009;16 Suppl 2:6-10.

Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res. 2009;15:224-31.

Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008;14:289-98.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353-60.

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011.

Comella CL, Simpson LL, Jankovic J. Botulinum toxins: Transformation of a toxin into a treatment. In: Waxman SG, ed. Neuroscience, Molecular Medicine, and the Therapeutic Transformation of Neurology, Elsevier/Academic Press, 2004:125-39.

Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W; Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65:1423-9.

Fahn S, Jankovic J. Principles and Practice of Movement Disorders, Churchill Livingstone, Elsevier, Philadelphia, PA, 2007:1-652. (Accompanied by a DVD of movement disorders.)

Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol. 2009;10(2):87-102.

Hou JG, Jankovic J. Botulinum toxin in the treatment of tremors. In: Brin MF, Hallett M, Jankovic J. Scientific and Therapeutic Aspects of Botulinum Toxin, Lippincott Williams & Wilkins, Philadelphia, PA, 2002:323-36.

Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009;16 Suppl 2:14-8.

Jankovic J: Botulinum toxin: Clinical implications of antigenicity and immunoresistance. In: Brin MF, Hallett M, Jankovic J. Scientific and Therapeutic Aspects of Botulinum Toxin, Lippincott Williams & Wilkins, Philadelphia, PA, 2002:409-16.

Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186-8.

Jankovic J, Esquenazi A, Fehling D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27:234-44.

Jankovic J. Dystonia: Medical therapy and botulinum toxin. In: Fahn S, Hallett M, DeLong DR, eds. Dystonia 4, Lippincott Williams & Wilkins, Adv Neurol. 2004;94:275-863.

Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19(Suppl 8):S109-15.

Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75:951-7.

Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotoxicity Research. 2006;9:145-8.

Jankovic J, Hunter C, Dolimbek BZ, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67:2233-5.

Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotoxicity Research. 2006;9:145-8.

Jankovic J, The treatment of dystonia. Lancet Neurol. 2006;5:864-72.

Jankovic J. Dystonic disorders. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders, 5th edition, Lippincott Williams and Wilkins, Philadelphia, PA, 2007:321-47.

Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8:844-56.

Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54:614-23.

Jankovic J (chief editor), Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N. Botulinum Toxin. Therapeutic Clinical Practice and Science, Saunders (Elsevier), Philadelphia, PA, 2009:1-492

Jankovic J. (2010) Botulinum Toxin. In: Kompoliti K, and Verhagen Metman L, eds. Encyclopedia of Movement Disorders, vol. 1, pp. 144-150, Oxford:Academic Press.

Jost WH, Blumel J, Grafe S. Botulinum neurotoxin Type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs. 2007;67:669-83.

Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115:585-91.

Kenney C, Jankovic J. Botulinum neurotoxin treatment of cranial-cervical dystonia. In: Jankovic J (chief editor), Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N. Botulinum Toxin. Therapeutic Clinical Practice and Science. Saunders (Elsevier), Philadelphia, PA, 2009:92-101.

Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomized, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264-70.

Kwak C, Jankovic J. Botulinum toxin type A in the treatment of tics. In: Brin MF, Hallett M, Jankovic J. Scientific and Therapeutic Aspects of Botulinum Toxin, Lippincott Williams & Wilkins, Philadelphia, PA, 2002:337-42.

Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord. 2005;20:592-7.

Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurologic Clinics. 2008;26(Suppl 1):43-53.

Moore AP, Ade-Hall RA, Smith CT, Rosenbloom L, Walsh HP, Mohamed K, Williamson PR. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology. 2008;71(2):122-8.

Morgan JC, Iyer SS, Moser ET, Singer C, Sethi KD. Botulinum toxin A during pregnancy: a survey of treating physicians. J Neurol Neurosurg Psychiatry. 2006;77:117-9.

Naumann M, Jankovic J. Safety of botulinum toxin type A: A systematic review and meta-analysis. Current Medical Research and Opinion. 2004;20:981-90.

Naumann M, So Y, Argoff CE, Childers MK, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1707-14.

Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62(1):37-40.

Papapetropoulos S, Singer C. Treatment of primary writing tremor with botulinum toxin type a injections: report of a case series. Clin Neuropharmacol. 2006;29:364-7.

Pappert EJ, Germanson T. The Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord. 2008;23:510-7.

Schulte-Mattler WJ. Use of botulinum toxin a in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs. 2008;22:725-38.

Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:74-93.

Sheffield JK, Jankovic J. Botulinum toxin in tic disorders and essential hand and head tremor. In: Truong D, Dressler D, Hallett M, eds. Manual of Botulinum Toxin Therapy, Cambridge University Press, 2009:195-204.

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1699-706.

Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1691-8.

Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A; BoNT/TZD Study Team. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80:380-5.

Tan E-K, Jankovic J. Treating severe bruxism with botulinum toxin. JADA. 2000;131:211-6.

Thomas M, Jankovic J. Tics, myoclonus, stiff person syndrome, gait freezing and rigidity. In: Moore P, Naumann M, eds. Handbook of Botulinum Toxin Treatment, 2nd ed., Blackwell Science, London, UK, 2003:325-39.

Tintner R, Jankovic J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. In: Brin MF, Hallett M, Jankovic J. Scientific and Therapeutic Aspects of Botulinum Toxin, Lippincott Williams & Wilkins, Philadelphia, PA, 2002:343-50.

Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65(5):765-7.

Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783-91.

Truong D, Comella C, Fernandez HH, Ondo WG; Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14:407-14.

Additional Information